• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization.

出版信息

Tuber Lung Dis. 1994 Jun;75(3):180-1. doi: 10.1016/0962-8479(94)90004-3.

DOI:10.1016/0962-8479(94)90004-3
PMID:7919308
Abstract
摘要

相似文献

1
The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization.利福平固定剂量复方制剂的前景与现状。国际防痨和肺部疾病联盟与世界卫生组织结核病规划联合声明
Tuber Lung Dis. 1994 Jun;75(3):180-1. doi: 10.1016/0962-8479(94)90004-3.
2
Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the World Health Organization.确保抗结核药物固定剂量组合的生物利用度。国际防痨和肺部疾病联盟与世界卫生组织联合声明。
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S282-3.
3
Efforts of the WHO/IUATLD to solve the problem of poor bioavailability of rifampicin from FDC anti-tuberculosis products: is a change required in the direction of the approach in view of recent findings?世界卫生组织/国际防痨和肺部疾病联盟解决固定剂量复方抗结核产品中利福平生物利用度差问题的努力：鉴于最近的研究结果，是否需要改变方法的方向？
Int J Tuberc Lung Dis. 2001 Sep;5(9):880-2.
4
The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S322-4; discussion S351-2.
5
Fixed-dose combination formulations for tuberculosis treatment.用于结核病治疗的固定剂量复方制剂。
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S286-8.
6
Structures required, roles and responsibilities in maintaining laboratories for quality assurance of anti-tuberculosis fixed-dose combinations in accordance with the IUATLD/WHO statement.
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S368-70; discussion S381-7.
7
Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption.利福平的生物利用度：对其药理学及确保最佳吸收的化疗必要性的综述。
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S301-8; discussion S317-21.
8
Statistical evaluation of physiological variability of rifampicin in fixed dose combinations.固定剂量复方制剂中利福平生理变异性的统计学评估。
Int J Pharm. 2006 Apr 26;313(1-2):5-13. doi: 10.1016/j.ijpharm.2005.12.049. Epub 2006 Mar 6.
9
Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.利福平、异烟肼和吡嗪酰胺在四种药物固定剂量组合与相同剂量水平的单独制剂中的相对生物利用度。
Int J Pharm. 2004 May 19;276(1-2):41-9. doi: 10.1016/j.ijpharm.2004.02.019.
10
Evaluation of rifampicin bioequivalence in fixed-dose combinations using the WHO/IUATLD recommended protocol.使用世界卫生组织/国际防痨和肺部疾病联盟推荐方案评估固定剂量复方制剂中利福平的生物等效性。
Int J Tuberc Lung Dis. 2000 Dec;4(12):1169-72.

引用本文的文献

1
Real-world impact of the fixed-dose combination on improving treatment outcomes of drug-susceptible tuberculosis: a comparative study using multiyear national tuberculosis patient data.固定剂量复方药物对改善耐多药结核病治疗结局的真实世界影响：基于多年全国结核病患者数据的对比研究。
BMJ Open Respir Res. 2023 Nov;10(1). doi: 10.1136/bmjresp-2023-001758.
2
An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis.757例肺结核患者抗结核药物性肝损伤或肝功能异常相关危险因素的调查
Front Pharmacol. 2021 Nov 8;12:708522. doi: 10.3389/fphar.2021.708522. eCollection 2021.
3
Health technology assessment of fixed-dose combination regimen in treatment of newly diagnosed smear-positive pulmonary tuberculosis: A meta-analysis.
固定剂量复方制剂治疗新诊断涂片阳性肺结核的卫生技术评估：一项荟萃分析。
Med J Armed Forces India. 2020 Apr;76(2):192-200. doi: 10.1016/j.mjafi.2018.12.002. Epub 2019 Mar 25.
4
Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: A retrospective cohort study.抗结核方案由三联变为四联对巴西结核患者的治愈率和不良反应发生率的影响：一项回顾性队列研究。
PLoS One. 2019 Dec 26;14(12):e0227101. doi: 10.1371/journal.pone.0227101. eCollection 2019.
5
Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.在两个结核病高负担非洲国家中，“固定剂量”与“松散”药物治疗方案治疗肺结核的疗效与安全性：一项随机对照试验
PLoS One. 2016 Jun 20;11(6):e0157434. doi: 10.1371/journal.pone.0157434. eCollection 2016.
6
Treatment of Drug Susceptible Pulmonary Tuberculosis.药物敏感型肺结核的治疗
Tuberc Respir Dis (Seoul). 2015 Jul;78(3):161-7. doi: 10.4046/trd.2015.78.3.161. Epub 2015 Jun 30.
7
Relative bioavailability of rifampicin in four Chinese fixed-dose combinations compared with rifampicin in free combinations.四种中国固定剂量复方制剂中利福平与游离利福平组合相比的相对生物利用度。
Chin Med J (Engl). 2015 Feb 20;128(4):433-7. doi: 10.4103/0366-6999.151061.
8
Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary disease.2014年呼吸系统综述：结核病和非结核分枝杆菌肺病
Tuberc Respir Dis (Seoul). 2014 Oct;77(4):161-6. doi: 10.4046/trd.2014.77.4.161. Epub 2014 Oct 31.
9
Assessing the risk of birth defects associated with exposure to fixed-dose combined antituberculous agents during pregnancy in rats.评估大鼠孕期接触固定剂量联合抗结核药物与出生缺陷相关的风险。
ScientificWorldJournal. 2012;2012:585094. doi: 10.1100/2012/585094. Epub 2012 May 3.
10
Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens.用于结核病的固定剂量复方药物：在标准化治疗方案中的应用
Drugs. 2003;63(6):535-53. doi: 10.2165/00003495-200363060-00002.